SAB Biotherapeutics elects four Class I directors, ratifies auditor at 2025 annual meeting

SAB Biotherapeutics, Inc.

Shareholders elected Dr. William Polvino, Scott Giberson, Erick Lucera, and Dr. Jay S. Skyler as Class I directors for three-year terms.
Appointment of EisnerAmper LLP as independent auditor for fiscal year 2025 ratified with 6,374,363 votes for, 238,327 against.
Quorum of 71.38% achieved; 6,633,125 shares present out of 9,291,697 outstanding.
Broker non-votes of 2,154,677 on director elections; each director received over 4.3 million votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.